2026 Biosimilar Medicines Conference
7–8 May 2026
Hilton Amsterdam Airport Schiphol
The Netherlands
Medicines for Europe Biosimilar Medicines Conference 2026
Home/Conferences
|
Posted 04/03/2026
0
Let’s Shape What’s Next:
Join us for the 2026 Biosimilar Medicines Conference!
At a pivotal moment when global trade tensions and strategic policy shifts – such as the conclusion of the revision of the EU pharmaceutical Legislation, or the Critical Medicines Act and Biotech Act – are reshaping the healthcare and pharmaceutical landscape, biosimilar medicines stand at the crossroads of access, sustainability, and industrial resilience.
This year’s Biosimilar Medicines Conference programme will explore how strategic coalitions for change can emerge across value chains, geographies, and stakeholders to unlock the full potential of biosimilar medicines to deliver meaningful impact for patients, health systems and society at large.
Together, we will address essential questions surrounding market competition, access strategies, regulatory evolution, competitiveness, health outcome improvements for Non-Communicable Diseases – all within the context of a rapidly evolving global ecosystem and emerging industrial policy frameworks.
Your expertise and insights are invaluable to these critical conversations. Save the dates and join us in May 2026 as we collectively shape the future of biosimilar medicines within health and industrial policy!
Register now and join us in The Netherlands!
Find out more details of the conference here.
Guidelines
US guidance to remove biosimilar comparative efficacy studies
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Policies & Legislation
China updates regulations to encourage research and innovation and improved drug safety
Brazil and Mexico forge alliance to streamline medical approvals and boost production
ASBM/GaBI 2024 webinar on BIOSIMILAR RED TAPE ELIMINATION ACT (S2305)
Home/Conferences Posted 05/11/2024
ASBM/GaBI 2023 webinar on INTERCHANGEABILITY DESIGNATION FOR BIOSIMILARS
Home/Conferences Posted 12/12/2023
The best selling biotechnology drugs of 2008: the next biosimilars targets